Xiaowei Zang

Xiaowei Zang

Auto-generated profile, based on publicly available information

Xiaowei Zang

Merck & Co., Inc. Rahway New Jersey USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
Jong Bong LeeJong Bong Lee
Jong Bong Lee
Atheer ZgairAtheer Zgair
Atheer Zgair
DTDhiaa A. Taha
Dhiaa A. Taha
XZXiaowei Zang
Xiaowei Zang
LKLeonid Kagan
Leonid Kagan
PGPavel Gershkovich
Pavel Gershkovich

27 November 2024 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
SMShabir A Madhi
Shabir A Madhi
ESEric Simoes
Eric Simoes
AAArmando Acevedo
Armando Acevedo
JPJose M Novoa Pizarro
Jose M Novoa Pizarro
JSJulie S Shepard
Julie S Shepard
ASAnushua Sinha
Anushua Sinha
Background: Clesrovimab is an investigational monoclonal antibody with an extended half-life targeting site IV of the respiratory syncytial virus (RSV) fusion protein for the prevention of RSV disease in infants. Methods: In this phase 1b/2a, double-blind study, 183 healthy preterm and full-term infants 2 weeks to 8 months of age were randomized 4:1 within 5 panels (preterm 20, 50, 75, or 100 mg; full-term 100 mg) to receive 1 dose of clesrovimab or placebo. The objectives were to evaluate safety, pharmacokinetics, serum neutralizing antibodies (SNA), and antidrug antibodies (ADA). The incidence of RSV-associated end points (medically attended lower respiratory tract infection, hospitalization, and acute respiratory infection) were also evaluated through 150 days postdose. Results: The most common adverse event through day 14 was irritability; no treatment-related serious AEs were reported. Clesrovimab serum concentrations displayed a geometric mean apparent half-life of 44.9 days. Of participants receiving clesrovimab, 51 (36.7%) developed ADA with no apparent impact in pharmacokinetics. SNA titers increased in a dose-dependent manner at day 150. The incidences of RSV-associated end points were lower in infants treated with clesrovimab compared with placebo. Conclusions: Clesrovimab was generally well tolerated and exhibited an extended half-life compared to typical IgG1 antibodies, supporting its ongoing development in late-stage trials. Clinical Trial Registration. NCT03524118.

29 November 2022 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Open access
RMRandolph P. Matthews
Randolph P. Matthews
XZXiaowei Zang
Xiaowei Zang
SBStephanie E Barrett
Stephanie E Barrett
AKAthanas Koynov
Athanas Koynov
AGAdrian Goodey
Adrian Goodey
MIMarian Iwamoto
Marian Iwamoto
Background: Islatravir (MK-8591) is a deoxyadenosine analog in development for the treatment and prevention of HIV-1 infection. An islatravir-eluting implant could provide an additional option for pre-exposure prophylaxis (PrEP). Setting: Previous data support a threshold islatravir triphosphate concentration for PrEP of 0.05 pmol/106 cells in peripheral blood mononuclear cells. Prototype islatravir-eluting implants were previously studied to establish general tolerability and pharmacokinetics (PKs) of islatravir relative to the threshold level. Methods: In this randomized, double-blind, placebo-controlled, phase 1 trial, a next-generation radiopaque islatravir-eluting implant (48 mg, 52 mg, or 56 mg) or placebo implant was placed for a duration of 12 weeks in participants at low risk of HIV infection. Safety and tolerability, as well as PK for islatravir parent and islatravir triphosphate from plasma and peripheral blood mononuclear cells, were assessed throughout placement and 8 weeks after removal. Results: In total, 36 participants (8 active and 4 placebo per dose arm) were enrolled and completed this study. Implants were generally well tolerated, with no discontinuations due to an adverse event, and no clear dose-dependence in implant-related adverse events. No clinically meaningful relationships were observed for changes in laboratory values, vital signs, or electrocardiogram assessments. Mean islatravir triphosphate levels at day 85 (0.101–0.561 pmol/106 cells) were above the PK threshold for all dose levels. Conclusion: Islatravir administered using a subdermal implant has the potential to be an effective and well-tolerated method for administering PrEP to individuals at risk of acquiring HIV-1.

16 April 2025 in Communications Medicine
Verified
Journal Article
Open access
PDF file
NPNele Plock
Nele Plock
JSJeffrey R. Sachs
Jeffrey R. Sachs
XZXiaowei Zang
Xiaowei Zang
JLJos Lommerse
Jos Lommerse
KVKalpit Vora
Kalpit Vora
BMBrian M. Maas
Brian M. Maas
Background: Respiratory syncytial virus (RSV) is a leading cause of respiratory tract infection in infants and young children. The level of serum neutralizing antibodies (SNAs) is often used as a measure of protection against respiratory syncytial virus (RSV) infection. Methods: A qualified, model-based, meta-analysis efficacy prediction framework was used to understand the maternal vaccination-induced fold-increase in SNA titers necessary to achieve, over several study observation periods and study populations, similar protection to that of the monoclonal antibody clesrovimab (MK-1654). Results: Simulations indicated that 3-month and 6-month efficacy comparable to that predicted for passive immunization (clesrovimab) would require a maternal vaccine to increase SNA titers by 30- and 60-fold, respectively, higher than observed increases reported to date. Efficacy of maternal vaccination was predicted (for vaccines similar to those with published data) to be substantially lower for preterm infants compared to full-term infants, and substantially less over 6 months than over 3 months. Efficacy of passive immunization was predicted to be similar or higher in preterm infants than full-term infants and was similar for 3- and 6-month observation periods. Conclusions: Modeling can be used to reliably predict the efficacy of maternal vaccination for preventing RSV in infants. Passive immunization (e.g., with clesrovimab) is likely to provide more protection for preterm infants and for infants born outside the RSV season than that provided by current maternal vaccines. Maternal vaccination may provide partial protection from RSV disease to full-term infants born just prior to or during the RSV season.

1 November 2021 in The Clinical Journal of Pain
Verified
Journal Article
Open access
MTMarko S. Md Todorovic
Marko S. Md Todorovic
KFKaren Crc Frey
Karen Crc Frey
RSRobert A. Swarm
Robert A. Swarm
MBMichael Bottros
Michael Bottros
LRLesley Rao
Lesley Rao
SHSimon Msc Haroutounian
Simon Msc Haroutounian
Objectives: Intravenous lidocaine can alleviate painful diabetic peripheral neuropathy (DPN) in some patients. Whether quantitative sensory testing (QST) can identify treatment responders has not been prospectively tested. Materials and Methods: This was a prospective, randomized, double-blind, crossover, placebo-controlled trial comparing intravenous lidocaine to normal saline (placebo) for painful DPN. Thirty-four participants with painful DPN were enrolled and administered intravenous lidocaine (5 mg/kg ideal body weight) or placebo as a 40-minute infusion, after a battery of QST parameters were tested on the dorsal foot, with a 3-week washout period between infusions. Results: Thirty-one participants completed both study sessions and were included in the final analysis. Lidocaine resulted in a 51% pain reduction 60 to 120 minutes after infusion initiation, as assessed on a 0 to 10 numerical rating scale, while placebo resulted in a 33.5% pain reduction (difference=17.6%, 95% confidence interval [CI], 1.9%-33.3%, P=0.03). Neither mechanical pain threshold, heat pain threshold, or any of the other measured QST parameters predicted the response to treatment. Lidocaine administration reduced mean Neuropathic Pain Symptom Inventory paresthesia/dysesthesia scores when compared with placebo by 1.29 points (95% CI, −2.03 to −0.55, P=0.001), and paroxysmal pain scores by 0.84 points (95% CI, −1.62 to −0.56, P=0.04), without significant changes in burning, pressing or evoked pain subscores. Discussion: While some participants reported therapeutic benefit from lidocaine administration, QST measures alone were not predictive of response to treatment. Further studies, powered to test more complex phenotypic interactions, are required to identify reliable predictors of response to pharmacotherapy in patients with DPN.

27 January 2026 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
ZHZiheng Hu
Ziheng Hu
FHFarina Hellmann
Farina Hellmann
XZXiaowei Zang
Xiaowei Zang
NPNele Plock
Nele Plock
KPKeyur Parmar
Keyur Parmar
FGFerdous Gheyas
Ferdous Gheyas
Clesrovimab is a half‐life extended monoclonal antibody targeting the respiratory syncytial virus fusion protein. Three studies (phase Ib/IIa [MK‐1654‐002], phase IIb/III [CLEVER], and phase III [SMART]) were conducted to evaluate the efficacy, safety, and pharmacokinetics (PK) of clesrovimab in infants. The objectives of this analysis were to develop an infant population PK model for clesrovimab and to evaluate the influence of intrinsic and extrinsic factors on clesrovimab PK in infants. A total of 5850 samples from 2942 participants were included in the population PK analysis. A two‐compartment model with first‐order absorption and elimination well described clesrovimab PK in infants. The estimated half‐life for clesrovimab was 44.0 days. Clearance, absorption rate constant, and central volume of distribution had low inter‐individual variability. Body weight was included as a covariate on all clearance and volume parameters, with estimated allometric scaling exponents centered on a body weight of 5 kg. A maturation function further described the change in clearance with increasing infant age. In addition to body weight and maturation function, the final model contained an effect of race on clearance. Although body weight, age, and race were identified as statistically significant covariates, the magnitude of the effect of these covariates on clesrovimab exposures was small (< 30%). The results of the population PK modeling support intramuscular administration of clesrovimab for the prevention of respiratory syncytial virus (RSV) disease in all infants, including healthy infants and infants at increased risk for severe RSV disease.